Industry Briefs: May 14, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Industry Briefs: May 14, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.


Company News

Almac has added the new PharmaWorks TF3, high-speed, large-format blister equipment, at its US headquarters in Souderton, Pennsylvania. Read More

GE Healthcare Life Sciences has completed its acquisition of Xcellerex. Read More

Molecular Profiles and GEA Process Engineering are collaborating to improve early screening of poorly water-soluble drugs and polymer compositions using the GEA Niro Drynetics single-particle spray-drying application.

Novozymes Biopharma has started to supply Novozymes Hyasis, a pharmaceutical-grade hyaluronic acid, from its recently opened facility in Tianjin, China. Read More

NSF-DBA has agreed with the Semler Research Center to expand pharmaceutical training, auditing, consulting, and testing services throughout India. Read More

People News

Cytovance Biologics has named Martin LeBlanc to its board of directors. Read More

Incline Therapeutics has appointed John Tucker as senior vice-president and chief commercial officer. Read More

Teva Pharmaceutical has appointed Michael Hayden as president of global R&D and chief scientific officer Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
9%
All of the above.
45%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing

Click here